Powered by AI-driven microbiome simulation, we are building a scalable product platform across disease and wellness areas.
Our first product for Dry Eye passed the clinical trials successfully. Further multiple solutions across emerging health categories are currently in development and to be launched in Q3 & Q4 2026
ENBIOSIS is a biotechnology company developing next-generation health products through AI-driven microbiome science.
Our technology enables the design of targeted, food-derived formulations that support the body’s own biological pathways across multiple disease and wellness areas.
A scalable product vision
Our platform is designed to address a wide range of microbiome-linked conditions and wellness needs, from chronic diseases to daily health optimization.
Eye Health & Dry Eye Support
Validated AI powder premixes ready for encapsulation or beverage integration. [Available Now]
Dry Eye was selected as the initial model indication due to its strong microbiome connection and clear clinical endpoints.
The product is designed to support tear production and ocular surface health by guiding microbiome-driven molecular pathways, ddressing the condition from within.
Seamless integration into our product portfolio
Our formulations are engineered exclusively for B2B scale. We deliver highly stable, standardized powder premixes that integrate flawlessly into your existing supply chain.
Transform our AI formulations into capsules, soluble sachets or functional food bars under your own brand name.
Secure your supply of AI-formulated premixes
ENBIOSIS is building a growing pipeline of microbiome-driven products across multiple disease and wellness areas.
Our technology, formulations, and clinical programs are progressing in parallel with creating long-term opportunities for strategic partners and investors.
Want to partner with us or get early access to our products? Get in touch with our experts to request samples, clinical data or to discuss other topics.
Learn more about our partnership models and how you can benefit from the ENBIOSIS technology.